- News & Features
New research suggests a combination approach in assessing quality of life for those with psoriatic arthritis through two out of three standard tools may be optimal.
The most talked about news coming out of the 2015 American College of Rheumatology annual meeting is showcased in a photo slideshow.
People who are controlling their rheumatoid arthritis with an anti-tumor necrosis factor (anti-TNF) drug may get sicker if they switch to a different one, researchers for AbbVie say.
Phase 1 research shared at the ACR 2015 annual meeting in early November highlighted the potential an investigational joint injection referred to as SM04690 may have to slow down the symptoms of knee OA—the most common form of arthritis in the knee.
Researchers have long debated the effectiveness of chonodroitin in treating osteoarthritis (OA). University of Montreal researchers are reporting daily intake of chonodroitin may slow the loss of cartilage in knee OA.
The American College of Rheumatology (ACR) published its guidelines for rheumatoid arthritis (RA) on November 6 online in the journal Arthritis Care & Research. It’s the first update to its guidelines since 2012, but the new guidelines do not address some of the hot topics in the field, including biosimilar drugs, biomarkers and pregnancy.
Studies comparing several upcoming biosimilar candidates to Humira (adalimumab) were presented at the American College of Rheumatology’s annual meeting this week and found clinical similarities to the widely-used biologic.
Research shows when patients with RA don't get relief from anti-TNFs, they may be better off switching to Orencia or rituximab rather than an anti-tumor necrosis drug.
The ACR shared its 2015 Guideline for the Treatment of Rheumatoid Arthritis this week during its annual meeting in San Francisco. CreakyJoints co-founder Seth Ginsberg helped provide the patient perspective during the development of the guidelines.
Why do rheumatoid arthritis patients so often see their condition differently from the way their doctors see it? Perhaps it’s because doctors aren’t looking at the big picture.
At the American College of Rheumatology Annual Meeting, Liana Fraenkel, MD, MPH,of Yale University School of Medicine, spoke about the feasibility of more integral patient involvement by developing clinical practice guidelines recommendations based on a voting panel composed entirely of patients.